Effect of micronized fenofibrate on vascular endothelial function in patients with hypertriglyceridemia

Chinese Medical Journal

Volumn 116, Issue 11, 2003, Pages 1767-1769

  Huang, Yun ^a,c   Dai, Guizhu ^a   Feng, Zongchen ^b   Lu, Chengfa ^a   Cheng, Bei ^a   Wang, Qiufen ^a   Nie, Fuding ^a   Li, Jingdong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Endothelium; Hypertriglyceridemia; Vasodilatation

Indexed keywords

ENDOTHELIN; FENOFIBRATE; GLYCERYL TRINITRATE; LIPID; TRIACYLGLYCEROL;

ADULT; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ECHOGRAPHY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; MALE; MEASUREMENT; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; PROCETOFEN; VASODILATION;

EID: 0346896369     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Selwyn AP, Kinlay S, Libby P, et al. Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Circulation 1997;95:5-7.
2. Ericsson CG, Hamsten A, Nilsson J, et al. An angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-853.
3. Hahmann HW, Bunte T, Hellwig N, et al. Progression and regression of minorcoronary arterial narrowings by quantitative angiography after fenofibrate therapy. Am J Cardiol 1991;67: 957-961.
4. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endotheliall dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-1115.
5. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998;81:18B-25B.
6. Reid VC, Mithchinson MJ. Toxicity of oxidized low-density lipoprotein towards mouse peritoneal macrophages in vitro. Atherosclerosis 1993;98:17-19.
7. Liao LK, Shin WS, Lee WY, et al. Oxidized LDL decrease the expression of endothelial nitric oxide synthase. J Biol Chem 1995;270:319-322.
8. Khan BV, Parthasarathy S, Alexander RW, et al. Modified low density lipoprotein and its constituents augement cytokinreactivated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 1995;95:1262-1265.
9. Hackman A, Abe Y, Insull W, et al. Levels of soluble adhesion molecules in patients with dyslipidemia. Circulation 1996;93:1334-1338.
10. Marx N, Sukhova GK, Collins T, et al. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999;99: 3125-3131.
11. Andrews TC, Whitney EJ, Green G, et al. Effect of gemfibrozil +/- niactin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl. Am J Cardiol 1997;80:831-835.
12. Ren M, Zeng Z, Liang YJ, et al. Effects of low density lipoprotein and high-density lipoprotein on nitric oxide synthesized by vascular endothelial cell. Chin J Arterioseler (Chin) 2000;8:134-136.